On March 1st, ANMAT met with four pharmaceutical chambers and called on them to be part of the Global Strategy against Antimicrobial Resistance (RAM). The move came amid implementation of Provision 7130/15, which regulates the sale of medicinal specialties whose active pharmaceutical ingredient (IFA) has antimicrobial activity. The meetings are set to continue in the coming months.
In the meeting, the parties committed to tackling the limitation of registering antibiotics that do not conform to the presentation recommendations according to specific active pharmaceutical ingredients (APIs). They also agreed that they will continue their joint work to establish the adequacy of the presentations of the products that are currently in the market and to adapt the samples without commercial value so that they adhere to the same presentation guidelines as the marketed products.
Participants in the meetings included the Argentine Chamber of Generic Medicines and Hospital Use Producers (CAPGEN), the Argentine Chamber of Medicinal Specialties (CAEMe), the Industrial Chamber of Argentine Pharmaceutical Laboratories (CILFA) and the Business Chamber of Pharmaceutical Laboratories (COOPERALA).